Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DM 199 (Primary) ; DM 199 (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms REMEDY; Remedy1
  • Sponsors DiaMedica Therapeutics
  • Most Recent Events

    • 14 Mar 2022 According to a DiaMedica Therapeutics media release, data from this study will be presented at the American Heart Association 2022 International Stroke Conference.
    • 11 Feb 2022 Results of post-hoc analysis assessing the effect of DM199 on the rate of stroke recurrence during a 90-day follow-up. Stroke recurrence after a primary stroke is associated with longer hospitalization and increased neurologic disability and death, presented at the International Stroke Conference 2022.
    • 25 Jan 2022 According to a DiaMedica Therapeutics media release, data from this study will be presented at the American Heart Association 2022 International Stroke Conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top